NCT01649570View on ClinicalTrials.gov

Safety and Efficacy of Insulin Aspart in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin aspart

Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks

Trial Locations (1)

103

Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY